When:
Friday, May 31, 2024 - 12:00am
Bayer’s Pharmaceuticals Research & Development division is working on potential future therapies for patients with Cardiomyopathies of a genetic background for whom a therapy is currently not available. We would like to use the stem cells to generate heart muscle cells and to investigate the differences of those cells in comparison to a healthy state to develop new therapeutic opportunities.